본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
사이트맵 닫기
Language
KOR
ENG
LinkedIn
YouTube
ESG
SK careers
C/S
SK ethics
Q
U
I
C
K
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Media Zoom
Press Releases
Media Zoom
Brochure
CI Guideline
Media Zoom
SK Bioscience begins ´globalization´ push, paying $244M for majority stake in contract manufacturer IDT Biologika
2024.06.07
SK bioscience, Sanofi ink contract for five types of vaccines
2024.03.27
SK bioscience devises new business strategy for post-pandemic era
2024.03.25
SK bioscience and IVI Announce 2024 Park MahnHoon Award Winners
2024.03.15
Novavax´s updated COVID-19 vaccine to help provide wider array of choices
2023.12.24
[From the Scene] SK bioscience rolls out Korea´s first cell-based flu vaccine
2023.08.23
SK bioscience breaks ground on Songdo R&PD Center
2023.06.22
[Herald Interview] Global teamwork key for future pandemic response: AstraZeneca co-developer
2023.05.01
SK bioscience to invest big in vaccines, CDMO over next 5 years
2023.04.28
SK bioscience to invest $1.8 bil. by 2027 to become top-tier bio firm
2023.04.28
SK bioscience to invest US$1.79 bln; eyes contract manufacturing deal
2023.04.28
SK Bioscience to invest W2.4tr by 2027
2023.04.28
처음
이전
1
2
3
4
다음
끝